Intestinal Organ-on-a-Chip Using Primary Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for drug development rely on animal models, which are costly, labor-intensive, and do not accurately predict human results, particularly for metabolism, transport, and oral absorption of drugs and nutrients.
Innovation Solution
The use of primary intestinal epithelial cells in organ-on-a-chip devices to create co-cultures of intestinal epithelium and endothelium, which support native intestinal structures and activities, is proposed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal models are used for drug development, then metabolic and transport data can be obtained, but the results do not accurately predict human outcomes and the process becomes costly and labor-intensive
Solution Approach 1:
The patent creates in vitro intestinal models that copy human intestinal tissue architecture and function, using primary human intestinal epithelial cells to form villi and multiple tissue layers that replicate native human intestinal structures. This allows direct human-relevant data without using animal models
Solution Approach 2:
The patent introduces microfluidic devices as an intermediary system between simple cell cultures and complex animal models. These devices provide controlled physiological conditions including peristaltic motion and fluid flow that mediate between in vitro and in vivo conditions, improving predictive accuracy while avoiding animal model complexity
2Shape
If tumor cell line-derived intestinal epithelial cells (e.g., Caco-2) are used, then intestinal epithelium can be formed, but native intestinal structures such as villi and multiple tissue layers cannot be supported
Solution Approach 1:
The patent changes the cellular composition parameter by using primary human intestinal epithelial cells instead of tumor cell lines. This parameter change enables the spontaneous formation of native intestinal structures including villi and multiple tissue layers, thereby improving both structural authenticity and physiological reliability
Solution Approach 2:
The patent introduces dynamic peristaltic motion to the culture system, which stimulates the intestinal epithelial cells to differentiate and form native structures such as villi. The dynamic mechanical stimulation mimics in vivo conditions and promotes authentic tissue architecture development
3Reliability
If in vitro models are developed to replicate actual intestinal tissue, then human-relevant data can be obtained, but the systems remain limited in supporting native intestinal structures and peristaltic activity
Solution Approach 1:
The patent designs microfluidic devices that perform multiple functions: they provide structural support for tissue formation, deliver nutrients and drugs, remove waste, apply mechanical stimulation, and enable real-time monitoring. This multi-functionality achieves human-relevant data while consolidating complexity into an integrated platform
Data Source
AI summary
Described herein are methods for providing an in vitro intestinal model system, e.g., using primary cells instead of cell lines and/or cancerous cells.